CTI BioPharma
CTIC
$9.09
Share price
0.00%
Change (1 day)
30.79%
Change (1 year)
Categories
CTI BioPharma (CTIC) - Total liabilities
Total liabilities on the balance sheet as of March 2023 : $0.13 B
According to CTI BioPharma 's latest financial reports the company's total liabilities are $0.13 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
CTI BioPharma - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $0.14 B | 108.98% |
| 2021-12-31 | $68.66 M | 277.04% |
| 2020-12-31 | $18.21 M | -35.76% |
| 2019-12-31 | $28.35 M | -23.16% |
| 2018-12-31 | $36.89 M | -4.91% |
| 2017-12-31 | $38.79 M | -30.83% |
| 2016-12-31 | $56.08 M | -42.13% |
| 2015-12-31 | $96.91 M | 80.12% |
| 2014-12-31 | $53.8 M | 5.58% |
| 2013-12-31 | $50.96 M | 25.01% |
| 2012-12-31 | $40.76 M | 19.1% |
| 2011-12-31 | $34.23 M | -41.72% |
| 2010-12-31 | $58.73 M | -33.53% |
| 2009-12-31 | $88.36 M | -52.97% |
| 2008-12-31 | $0.18 B | 3.58% |
| 2007-12-31 | $0.18 B | -10.83% |
| 2006-12-31 | $0.20 B | -22.52% |
| 2005-12-31 | $0.26 B | 2.67% |
| 2004-12-31 | $0.25 B | 11.84% |
| 2003-12-31 | $0.22 B | 59.55% |
| 2002-12-31 | $0.14 B | -26.21% |
| 2001-12-31 | $0.19 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $53.19 B | 38,553.82% | 🇨🇭 Switzerland |
 Eli Lilly LLY | $53.14 B | 38,515.74% | 🇺🇸 USA |
 Amgen AMGN | $90.92 B | 65,967.91% | 🇺🇸 USA |
 Baxter BAX | $19.80 B | 14,293.36% | 🇺🇸 USA |
 Incyte INCY | $1.59 B | 1,057.01% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $65.67 B | 47,621.61% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $35.35 B | 25,589.04% | 🇮🇱 Israel |